Top Tweets for #smallcapable
Good analysis of the latest results of Transrail Lighting by @arjunjain_96
#smallcapable
Focusing on positives - Top 3 standout pointers:
1. Superb full year execution with a massive 30% YoY revenue growth for the full fiscal year FY26
2. Margins defended in double digits despite the cost pressures and inflation that hit the sector in Q4
3. Large capacity expansion completed with a major greenfield expansion at its Butibori plant and partial brownfield expansions across Deoli, Baroda, and Silvassa. This effectively more than doubled their total installed tower manufacturing capacity from 84,000 MTPA to 172,400 MTPA.
Transrail Lighting FY26 results out.
Full year: strong - highest ever revenue, EBITDA and PAT.
Q4: softer than expected with real headwinds behind it.
For an EPC company, the P&L is only part of the story.🧵
Truly... A business that delivers that too consistently and silently...
Pricol
#smallcapable
A business that kept delivering silently in Auto Ancs
PRICOL
Disc: no reco to buy or sell.
Fiem Industries
#smallcapable
The EU-India FTA positions Fiem Industries for net positive growth through enhanced EU market access, though the full impact will unfold over the next few years.
The agreement eliminates or reduces tariffs on over 96% of EU goods exports to India and 99% of Indian exports to the EU. For auto parts and components, duties will be fully abolished in phases over 5-10 years.
Reduced barriers may encourage EU OEMs (e.g. Volkswagen, BMW) to source more from Indian suppliers like Fiem, potentially leading to new contracts, joint ventures or local manufacturing tie-ups. Lower tariffs could increase Fiem's shipments to the EU, boosting revenue.
What do you think?
Belrise Industries
#smallcapable
Strategic Partnership with Plasan Sasa (Announced December 22, 2025):
Belrise Industries entered into an agreement with Plasan Sasa (Israel), a global leader in advanced armour and survivability solutions, to jointly pursue opportunities in the Indian military market. The focus is on the ATEMM (All-Terrain Electric Mission Module) series—a cutting-edge self-propelled electric platform enhancing payload, energy, survivability, and mobility for armed forces.
This collaboration leverages Belrise's manufacturing strength in India and Plasan's expertise, aiming to adapt the platform for Indian defence needs. This move expands Belrise's presence into defence-related manufacturing, beyond its core automotive portfolio.
Good prospects ahead for Belrise.
3 reasons why Fiem Industries is trading at all time high prices?
#smallcapable
Fiem Industries Ltd, a leading auto components manufacturer specializing in lighting and plastic parts for two-wheelers and increasingly four-wheelers, has seen its stock price surge to an all-time high of ₹2,378.10 in the 52-week period, with the current price hovering around ₹2,272-2,273 as of December 11, 2025 (up ~1.3% intraday). This represents a 41-47% gain over the past year and a remarkable 900% rise over five years, driven by a combination of stellar financial performance, sector tailwinds, and investor enthusiasm.
Below are the top 3 factors contributing to this rally:
1. Record-Breaking Q2 FY26 Earnings (Ended September 2025)
The company reported its highest-ever quarterly sales of ₹711-715 crore, a 17% year-over-year (YoY) increase, fueled by robust original equipment manufacturer (OEM) demand.
EBITDA margins expanded to 13.93% from 13.21% YoY, reflecting improved operational efficiency and cost controls.
Profit before depreciation, interest, and taxes (PBDIT) hit a record ₹99 crore, with net profit at ₹63.67 crore.
This marks seven consecutive quarters of positive results, underscoring sustained momentum.
2. Strong Demand from Key Two-Wheeler OEMs and Segment Shift
Explosive growth in the two-wheeler segment, which now dominates revenue (passenger vehicle contribution dipped to 2.3% from 5-7% due to this shift), driven by major clients like Royal Enfield (6% sales contribution, expected to rise with new model volumes), Yamaha, and Mahindra.
New model launches incorporating advanced technologies, such as animated headlamps and rear lamps, have boosted order inflows.
The Indian two-wheeler market's recovery post-pandemic, coupled with export growth, has positioned Fiem as a key beneficiary.
3. Strategic Expansion into Four-Wheelers and Global Markets
Recent wins include lighting component orders from Mahindra for four-wheelers, signaling diversification beyond two-wheelers.
Investments in R&D for next-gen technologies (e.g., LED and adaptive lighting) are opening doors to global OEMs, with inroads into international markets anticipated.
Shriram Pistons and Rings (SPRL) at ATH. Why?
#smallcapable
While the fundamentals were always improving the primary catalyst for current buzz is SPRL's major acquisition announcement on December 5, 2025, which has sparked widespread optimism about diversification and long-term growth.
The company signed a definitive Share Purchase Agreement (SPA) with Spain-based Grupo Antolin Irausa S.A.U. and Grupo Antolin Ingenieria S.A.U. to acquire 100% of three Indian subsidiaries:Antolin Lighting India Pvt. Ltd. (ALIPL)
Grupo Antolin India Pvt. Ltd. (GAIPL)
Grupo Antolin Chakan Pvt. Ltd. (GACPL, a subsidiary of GAIPL)
Valued at approximately €159 million (₹1,670 crore on a debt-free, cash-free basis), the deal is expected to close by January 2, 2026, pending regulatory approvals.
This marks SPRL's strategic entry into the high-growth automotive interiors segment (e.g., headliners, door panels, and lighting systems), moving beyond its core engine components business. The acquired entities supply to global OEMs like Volkswagen, Ford, and Hyundai, adding scale, customer diversity, and synergies in EV/hybrid interiors.
Very positive for Shriram Pistons & Rings. Company appears to be doing great all right things. Very consistent performance.
#smallcapable
🚀 Shriram Pistons & Rings Expands with Grupo Antolin Acquisition | MCap 13,185.87 Cr
- Shriram Pistons & Rings (SPRL) is acquiring Antolin Lighting India, Grupo Antolin India, and Grupo Antolin Chakan.
- The proposed completion date for the acquisition is December 5, 2025.
- The transaction is subject to closing conditions outlined in the Share Purchase Agreement.
- SPRL clarified that recent trading volume changes were market-driven, not due to undisclosed information.
- The company confirmed compliance with SEBI Listing Regulations.
Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.
Stylam Industries has silently given 31% returns in last 3 months.
Fundamentals are great but the special situation (if it takes place) can take it to next orbit.
#smallcapable
Do you know which is Belgium’s second-largest city and one of the world’s major ports?
What's behind the name of the city?
#smallcapable
With such numbers in the picture, at least it deserves a PEG of 1 and PE of 25+ as like other peers.
Keeping aside the M&A transaction - this company still appears undervalued.
#smallcapable
Anything missing here.
Who is forging cignature?
Can just plain and boring rental business make this company a multibagger?
Probably...Results have slowly started to indicate that.
Tara Chand Infralogistic Solutions Ltd
#smallcapable
Company with good propects.
#SmallCapable
Tarachand Infralogistics stands out as a candidate for investment due to its strong growth record, improving efficiency, favorable sector tailwinds, and a strategic shift into high-yield segments and marquee clients. Financial ratios and balance sheet indicators point toward a healthy, growing company, though investors should be mindful of recent share price volatility and cyclical risks. Its unique positioning in the logistics-equipment rental space and exposure to the capex upcycle could offer upside, but assessing entry price is important.
16X.. Yes 16X returns in Knowledge Marine in just 3.5 years that too after being 4X just 1 year before. Worth mentioning "Maine Bola Tha" :-)
#smallcapable
For those who are bullish on sustainable packaging as a theme, Mamata Machinery is an i teresting proxy.
#smallcapable
Belrise has posted powerful numbers. Appears to be a promising company.
#smallcapable
Superb results by FIEM once again
#smallcapable
#SmallCapable 02
Fiem Industries Ltd is a consistent performer and working like a mean profit growing machine. It has shown 20% + profit growth in last 5 years. Sales is also growing tremendously. With ROCE of ~30% and ROE of 21%, this is a hugely efficient company in automotive lighting segment. Is there anything about the company that is not so great? - minor reduction in the promoter holding but still held well by promoters and equally supported by FIIs and DIIs. It has received multiple awards but the one that catches the eye most is the Award for Best Supplier from Honda Motorcycle & Scooter India.
One prominent small cap fund is increasing its stake in Fiem gradually. This is a Zero debt, 10 Rs face value stock, with a decent dividend distribution for a small cap company.
This stock and company will continue to do well in near future. CMP INR 1965, MCAP INR 5184 CR
I am tracking Kilburn engineering from some time now and it is not disappointing at all.
Superb results.
#smallcapable
#KLBRENG_B Kilburn Engineering: Blockbuster #Q2FY25
Sales, Margin and Profits all improved both YoY and QoQ
This is such an underrated company because of being listed just on BSE.
Momentum above 575 to kick in !!
How are these numbers appearing for a company having market cap of 500 Cr and the stock price is less than a kg of tomato?
#SMALLCAPABLE
Did not find a lot of information on the company and promoters/business online or outside their results filing and website.
Any thoughts?
DISC: TO BE STUDIES AND NOT AN INVESTMENT CANDIDATE YET
GPT healthcare - Latest Results & Management quality
DISC - No recommendation, only tracking the company as the business model appears promising
#smallcapable
Positives:
1. Operational Resilience: All 4 hospitals scaled efficiently, with ARPOB growth signaling premiumization (e.g., higher realizations in cardiology, ortho). Volume uptick from walk-ins and insurance ties reflects strong regional moat in West Bengal/Tripura.
2. Margin Stability: EBITDA margins held at 19-20%, better than industry avg. (~15-18% for mid-sized chains), thanks to low fixed costs and diversified specialties (no single one >20% revenue).
3. Strategic Moves: Earnings call (Oct 2024) emphasized tech integration (mobile app launch) and dividend claims drive, boosting investor relations. Debt reduction post-IPO supports RoCE (~15-18%, est.).
4. Market Context: Aligns with India's healthcare tailwinds (market to ₹9.2-9.3 Tn by FY28); GPT's mid-sized model avoids overcapacity risks seen in larger peers.
Concerns:
1. Growth Moderation: YoY revenue 12-15% lags Q1 FY26 (18%) and FY25 (~20% CAGR), possibly from monsoon-related elective procedure dips. PAT growth muted due to one-offs (e.g., higher provisions).
2. No Major Expansion: No new beds added in Q2; focus on organic ramp-up limits top-line upside. Competition from Apollo/Fortis in Eastern India could pressure ARPOB if pricing wars intensify.
3. Valuation Check: At current price (~₹151, Nov 2025), trades at ~25-28x FY26 EPS – reasonable vs. peers
Overall View: Nothing wrong in the Results or negatively surprising. Results underscore steady execution in a defensive sector, with healthy cash flows (OPCF ~₹150 Mn est.) funding growth without dilution. Expect FY26 revenue ~₹420-440 Cr (+15% YoY), PAT ~₹50 Cr.
Monitor Q3 for expansion cues.
A small comment on the management quality as inquired by fellow members of the community -
These are strong operational promoters with a proven healthcare build-out in a fragmented Eastern India market. The family's diversified GPT Group backing adds resilience, but adding more independent expertise could elevate governance. No red flags on ethics or value destruction; they've focused on sustainable growth over aggressive expansion.
GPT Healthcare : A nimble hospital company at low valuations (with a reason)
Worth Investing or not?
#smallcapable
Disc: Not a recommendation
Business Overview
GPT runs a compact network of mid-sized multi-specialty hospitals: 3 in Kolkata, 1 each in Agartala and newly launched Raipur (total 561 beds in FY25). FY25 revenue: ₹407 crore; occupancy 53%; ARPOB ₹37,180. Largely cash-driven (private/insurance patients), low debtor days, high cash conversion (~80% of EBITDA).
Why the Valuation Discount?
Smaller scale leads to volatile metrics (occupancy/ARPOB fluctuations during ramp-ups) vs. larger peers like Yatharth (mid-60s occupancy). Market prices in this lumpiness, resulting in lower multiples.
Structural Opportunity
Eastern India underpenetrated by corporate chains; rising incomes/populations in Kolkata/Raipur but limited organized supply. GPT's asset-light, mid-sized model targets Tier-2/3 cities, serving local and referral patients lacking quality care.
Expansion Strategy
Raipur (158 beds) operational; Jamshedpur (150 beds) signed.
Target: 1,000 beds in 2–2.5 years.
Asset-light: Lease buildings + ₹65 crore fit-out (vs. ₹100 crore owned); negligible net debt; fund internally via strong cash flows (equity only for extras).
Key Operational Levers
ARPOB Growth: Up to ₹38,900 in Q1 FY26 via high-value upgrades (robotics, cardiology, neurosurgery, oncology in Agartala).
ALOS Reduction: From 5.6 days (FY21) to 3.5 days (FY25)/3.46 (Q1 FY26) → boosts throughput/revenue efficiency.
Flexible Doctors: All contracted (revenue-share/per-case); higher payouts early (mid-30s%) but normalize with volume; enables quick specialty additions without fixed costs.
Growth Potential & Risks
Conservative: 1,000 beds @ 50% occupancy, ₹36,000 ARPOB → ~₹657 crore revenue by FY27 (mid-teens CAGR from ₹407 crore).
Risks: Raipur/Jamshedpur ramp-up delays, no further sites, consultant churn. Mitigations: Faster oncology/robotics rollout, referral expansion, asset-light replication.
Investment Thesis
At ~25x earnings, priced for a cash-efficient regional operator, not perfection. Breakeven ~35% occupancy; economics improve sharply toward 50–60%. Execution on utilization/case-mix could drive re-rating and market-beating returns. A unglamorous but credible Eastern India play with mid-teens growth if delivered.
Please study the company, not a recommendation for investment.
BLACKBUCK LIMITED Q2FY26:-
#blackbuck #Q2Results #Q2FY26 #Nifty #StockMarket
Total Income ₹167.2 Cr (+60.35% YoY)
Net Revenues ₹135.86 Cr (+37.55% YoY)
Adjusted EBITDA ₹42.69 Cr (+122.89% YoY)
EBITDA ₹36.5 Cr (+142.8% YoY)
PAT ₹29.20 Cr vs -₹ 269.47 Cr YoY
Transacting Customers: 7.92 lakh (+13.2% YoY)
Users (using ≥2 services): 3.99 lakh (+21.2% YoY)
GTV of Payments: ₹6,778 Cr (+28.7% YoY)
Business Performance:-
1) Core Businesses (Payments & Telematics)
Revenue: ₹123.35 Cr (+36.7% YoY, +3% QoQ)
Growth led by Tolling, Telematics, and Fuel Sensor products (fuel sensor sales up 55% QoQ)
Continued investments in sales & distribution network
2) Growth Businesses (SuperLoads, Vehicle Finance)
Revenue: ₹27.79 Cr (+226% YoY, +19% QoQ)
SuperLoads gaining strong traction — plans to expand to 10 new cities in next 6 months.
Vehicle Finance scaling up through partner-led model
EBITDA improvement driven by cost efficiencies, operating leverage, and disciplined investments
One small cap squality stock in this sector that will continue to compound consistently appears to be KMCH OR Kovai Medical.
From all parameters it appears safe, growing and efficient.
#smallcapable
Hospital and HealthCare Sector in India
India's hospital sector stands at an inflection point, presenting compelling structural growth drivers combined with substantial infrastructure gaps. The sector is poised for significant expansion over the coming decade, driven by demographic tailwinds, policy support, insurance penetration, and private sector capital allocation.
The Indian healthcare market is valued at approximately $180 billion as of 2024 and is projected to reach $638 billion by 2025, reflecting a 22.5% CAGR during recent periods. Within this broader ecosystem, the hospital sector dominates, accounting for approximately 80% of total healthcare spending. The hospital industry specifically is expected to grow at a 10.64% CAGR from 2025-2030, expanding from $108.57 billion in 2024 to $197.31 billion by 2030. This represents a near-doubling of hospital sector value within a six-year window.
But the problem for investors is that most of the companies in the sector are already trading at higher valuations.
Is there any hospital company that is growing well and consistently, growing its profits consistently, doesn't carry big debt and still available at decent valuations.
Comment if you know of any such companies?
Last Seen Hashtags on Sotwe
somno
Seen from Germany
برايفت_تانجو
Seen from Germany
야동
Seen from Korea
nolimit()filter:media() - filter:images
Seen from United States
BolehKanya
Seen from Korea
saggy
Seen from Germany
denisescottbrown_azw
Seen from Korea
momson()* + filter:native_video
Seen from Singapore
ซิกแพ็ค
Seen from Thailand
konbrut
Seen from Malaysia
Most Popular Users
Elon Musk 
@elonmusk
240.8M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
111.2M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.8M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91M followers
KATY PERRY
@katyperry
88M followers
Taylor Swift
@taylorswift13
81.8M followers
Lady Gaga
@ladygaga
73.3M followers
Virat Kohli
@imvkohli
70.4M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.1M followers
Neymar Jr
@neymarjr
63.2M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61M followers
X
@x
60.8M followers